logo

Shield Therapeutics PLC - Feraccru: a potential game changer in the treatment of iron deficiency anaemia

Written by Riccardo Lowi

Feraccru is a unique, non-salt, formulation oral iron: strong efficacy with “placebo-like” tolerability

Potential to change iron deficiency anaemia (IDA) therapeutic algorithm

Feraccru to become the preferred option for patients not adequately controlled or who are intolerant to generic oral iron supplements (before they switch to intravenous iron).

With an indication in Europe to treat iron deficiency, Feraccru’s use would prevent the occurrence/reoccurrence of iron deficiency anaemia

Feraccru European commercialisation expected to accelerate significantly following the licensing agreement with Norgine announced in September 2018

Key upcoming milestones: results of the head-to-head phase 3 study of Feraccru vs intravenous (i.v.) iron expected in first half (1H) of 2019; Feraccru PDUFA (Prescription Drug User Fee Act) date 27 July 2019

Current market capitalisation of about £40mln is by and large not reflecting Feraccru commercial potential

Shield’s lead asset Feraccru is a novel and highly differentiated iron formulation, for oral administration, indicated for the treatment of iron deficiency, i.e. low levels of iron body stores, usually caused by blood loss or malabsorption.

FULL REPORT CONTINUES…

Shield Therapeutics PLC Timeline

Latest Research